RS Investment Management Co. LLC raised its stake in shares of Loxo Oncology Inc. (NASDAQ:LOXO) by 7.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,505,004 shares of the biopharmaceutical company’s stock after buying an additional 98,038 shares during the period. RS Investment Management Co. LLC owned 0.08% of Loxo Oncology worth $34,886,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the stock. Adage Capital Partners GP L.L.C. boosted its stake in Loxo Oncology by 40.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 700,000 shares of the biopharmaceutical company’s stock valued at $19,138,000 after buying an additional 200,000 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Loxo Oncology by 17.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 148,490 shares of the biopharmaceutical company’s stock valued at $4,060,000 after buying an additional 21,737 shares in the last quarter. State Street Corp boosted its position in shares of Loxo Oncology by 7.4% in the first quarter. State Street Corp now owns 133,074 shares of the biopharmaceutical company’s stock valued at $3,638,000 after buying an additional 9,142 shares in the last quarter. TIAA CREF Investment Management LLC boosted its position in shares of Loxo Oncology by 7.9% in the first quarter. TIAA CREF Investment Management LLC now owns 28,706 shares of the biopharmaceutical company’s stock valued at $785,000 after buying an additional 2,113 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Loxo Oncology by 3.9% in the first quarter. Geode Capital Management LLC now owns 57,068 shares of the biopharmaceutical company’s stock valued at $1,560,000 after buying an additional 2,126 shares in the last quarter. 95.46% of the stock is owned by institutional investors and hedge funds.

Loxo Oncology Inc. (NASDAQ:LOXO) traded up 1.62% during trading on Thursday, hitting $27.00. The stock had a trading volume of 104,631 shares. The firm’s 50-day moving average price is $26.91 and its 200-day moving average price is $25.09. Loxo Oncology Inc. has a 1-year low of $16.21 and a 1-year high of $35.00. The stock’s market cap is $584.93 million.

Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.14. On average, equities research analysts predict that Loxo Oncology Inc. will post ($2.83) earnings per share for the current fiscal year.

Several equities analysts recently issued reports on the company. Zacks Investment Research cut Loxo Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, September 6th. Cowen and Company reaffirmed a “buy” rating on shares of Loxo Oncology in a report on Wednesday, July 13th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $29.60.

In other news, Director Keith T. Flaherty sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $26.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now directly owns 60,482 shares of the company’s stock, valued at $1,572,532. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Keith T. Flaherty sold 14,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $30.00, for a total value of $435,000.00. Following the transaction, the director now directly owns 45,982 shares of the company’s stock, valued at $1,379,460. The disclosure for this sale can be found here. Insiders own 44.40% of the company’s stock.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

5 Day Chart for NASDAQ:LOXO

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc. (NASDAQ:LOXO).

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.